Poltreg (PTG) Q1 2026 earnings summary

Executive summary

• Focus on developing innovative Treg-based cell therapies for autoimmune diseases, with a leading global position in clinical development for type 1 diabetes and multiple sclerosis.

• Achieved key milestones: eligibility letter from EMA for PTG-007, first GMP batch of CAR-TREG, and a licensing deal with City of Hope for CAR-Treg technology.

• Raised 18.8 million PLN in a secondary public offering, increasing share capital to 591,645.60 PLN.

Financial highlights

• Q1 2026 revenue: 2,582 thousand PLN, up from 1,798 thousand PLN year-over-year.

• Net loss: 6,782 thousand PLN, compared to 5,471 thousand PLN in Q1 2025.

• Operating cash flow: -8,410 thousand PLN (Q1 2025: -4,592 thousand PLN).

• Cash at period end: 9,120 thousand PLN, down from 17,785 thousand PLN at year-end 2025.

• Equity: 36,616 thousand PLN; total assets: 65,032 thousand PLN as of March 31, 2026.

Outlook and guidance

• Strategic focus on partnering with major pharma for commercialization and further clinical development.

• Plans for additional fundraising in 2027 if needed to reach key milestones.

• Ongoing efforts to accelerate patient recruitment in preTreg clinical trials and expand R&D in the US.